Patrick J. McEnany - 20 Nov 2025 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Reporting relationship: Director, Chairman of Board of Directors
Issuer ticker: CPRX
Reported as of: 20 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Nov 2025, 20:08:29 UTC
Prior SEC filing: 10 Jun 2025
Next SEC filing: 03 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Patrick J. McEnany

Key filing fact

Patrick J. McEnany filed Form 4 for CATALYST PHARMACEUTICALS, INC. (CPRX) on 24 Nov 2025.

Key facts

This page summarizes Patrick J. McEnany's Form 4 filing for CATALYST PHARMACEUTICALS, INC. (CPRX).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 24 Nov 2025, 20:08.

Change

Previous filing in this sequence was filed on 10 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0000929985 Primary reporting owner

MCENANY PATRICK J

Relationship: Director, Chairman of Board of Directors
Address: 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES
Signature: /s/ Patrick J. McEnany
Signature date: 24 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CPRX transaction

Common Stock, par value $0.001 per share

Options Exercise

Transaction value
Shares: +1,775
Change %: +0.04%
Price
Shares after: 4,283,477
Date: 21 Nov 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CPRX transaction Derivative

Options to purchase common stock

Award

Transaction value: $0
Shares: +34,921
Change %: +1.9%
Price: $0.000000
Shares after: 1,873,051
Date: 20 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,921
Exercise price: $22.77
Footnotes: F2

CPRX transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +10,540
Change %: +0.56%
Price: $0.000000
Shares after: 1,883,591
Date: 20 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,540
Exercise price
Footnotes: F2, F3

CPRX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -1,775
Change %: -0.09%
Price: $0.000000
Shares after: 1,881,816
Date: 21 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,775
Exercise price
Footnotes: F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.

Footnote F2

Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028.

Footnote F3

Shares of common stock will be delivered to the Reporting Person upon vesting.

Footnote F4

Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027.

Footnote F5

Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.